Pharvaris N.V.

Pharvaris does not sell broad consumer products; its end users are patients with rare bradykinin-mediated diseases, while its immediate commercial counterparts are physicians, specialty distributors, and healthcare systems that would prescribe, stock, and administer approved therapies. In the development stage, the company’s economic relationship is primarily with regulators, investigators, clinical sites, and future payers that determine access and reimbursement. Rare-disease treatments are typically bought because they address serious unmet medical need and can offer differentiated convenience or efficacy.

The company’s strategy is to advance its rare-disease pipeline through clinical development and regulatory review, then position candidate therapies for commercialization if approved. It is also building the operational and corporate structure needed to support global development and future launch in target markets where hereditary angioedema is treated. Protecting intellectual property and maintaining access to funding are central because the model depends on completing long development cycles before meaningful product revenue.